DILIC
ALNY icon

Dai-ichi Life Insurance Company’s Alnylam Pharmaceuticals ALNY Stock Holding History

Dai-ichi Life Insurance Company’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Sell
5,873
-57
-1% -$17.2K 0.04% 295
2026
Q1 		$1.96M Sell
5,930
-325
-5% -$111K 0.06% 256
2025
Q4 		$2.49M Buy
6,255
+800
+15% +$354K 0.06% 237
2025
Q3 		$2.49M Buy
5,455
+2,000
+58% +$814K 0.06% 242
2025
Q2 		$1.13M Buy
3,455
+2,500
+262% +$692K 0.03% 343
2025
Q1 		$258K Hold
955
– – 0.01% 474
2024
Q4 		$225K Hold
955
– – 0.01% 476
2024
Q3 		$263K Sell
955
-122
-11% -$31.8K 0.01% 475
2024
Q2 		$262K Buy
+1,077
New +$170K 0.01% 437
2023
Q4 		– Sell
-7,100
Closed -$1.26M – 463
2023
Q3 		$1.26M Buy
7,100
+504
+8% +$96.2K 0.03% 344
2023
Q2 		$1.25M Sell
6,596
-383
-5% -$75.9K 0.03% 351
2023
Q1 		$1.4M Hold
6,979
– – 0.03% 337
2022
Q4 		$1.66M Buy
6,979
+4,040
+137% +$862K 0.04% 319
2022
Q3 		$588K Hold
2,939
– – 0.01% 419
2022
Q2 		$429K Hold
2,939
– – 0.01% 444
2022
Q1 		$480K Hold
2,939
– – 0.01% 460
2021
Q4 		$498K Sell
2,939
-418
-12% -$77.7K 0.01% 464
2021
Q3 		$634K Hold
3,357
– – 0.01% 457
2021
Q2 		$569K Hold
3,357
– – 0.01% 468
2021
Q1 		$474K Hold
3,357
– – 0.01% 470
2020
Q4 		$436K Sell
3,357
-3,918
-54% -$523K 0.01% 451
2020
Q3 		$1.06M Hold
7,275
– – 0.02% 381
2020
Q2 		$1.08M Sell
7,275
-261
-3% -$35.2K 0.02% 362
2020
Q1 		$820K Hold
7,536
– – 0.03% 383
2019
Q4 		$868K Buy
7,536
+214
+3% +$21.3K 0.02% 427
2019
Q3 		$589K Hold
7,322
– – 0.01% 449
2019
Q2 		$531K Hold
7,322
– – 0.01% 464
2019
Q1 		$684K Buy
+7,322
New +$612K 0.02% 438

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dai-ichi Life Insurance Company's ALNY Position: Q2 2026 in Review

Dai-ichi Life Insurance Company reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.96% in Q2 2026, selling an estimated $17.2K and leaving 5,873 shares worth $1.77M. The position accounts for 0.04% of the portfolio, ranked #295.

Dai-ichi Life Insurance Company first reported a position in ALNY in Q1 2019 and has held it in 28 quarters since. The position peaked at $2.49M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Dai-ichi Life Insurance Company held 5,873 shares of Alnylam Pharmaceuticals worth $1.77M as of Q2 2026.
  • Dai-ichi Life Insurance Company sold 57 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $17.2K.
  • Alnylam Pharmaceuticals made up 0.04% of Dai-ichi Life Insurance Company's portfolio in Q2 2026, its #295 holding.
  • Dai-ichi Life Insurance Company first reported a position in Alnylam Pharmaceuticals in Q1 2019 and has held it in 28 quarters since.
  • Dai-ichi Life Insurance Company's Alnylam Pharmaceuticals position peaked at $2.49M in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Dai-ichi Life Insurance Company's 13F filing for Q2 2026, filed 12 Aug 2026.